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Abstract
Background: Appropriate cessation of chemotherapy and timely referral of patients to hospice services are crucial
for the quality of care near death. We investigated the quality of care in our Cancer Institute in very advanced
metastatic colorectal cancer patients treated in real life.
Patients and Methods: We performed a retrospective analysis of electronic medical data of patients with
metastatic colorectal cancer who were candidates for chemotherapy during the study period (1 January 2007–30
June 2014) and died before 31 December 2014. Quality-of-cancer-care indicators were calculated for the overuse of
chemotherapy and referral to hospice. Predictive factors of chemotherapy discontinuation and hospice referral in
end-of life care were investigated using parametric and nonparametric methods.
Results: Of the 365 patients who died before 31 December 2014, 26 (7.1%) received chemotherapy in the last
14 days of life and 36 (9.8%) started a new chemotherapy regimen in the last 30 days of life. Factors associated
with the overuse of chemotherapy were being < 70 years of age for both indicators and not having received
advanced chemotherapy treatments for the former indicator. The majority of patients (74.7%) had access to hospice
services, of whom only a small percentage (7.2%) accessed them very near to death.
Conclusions: According to the criteria used, our Institute provides a good quality of cancer care for dying
colorectal cancer patients, measured by the use of chemotherapy and referral to hospice in their last days of life.
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Background
Despite the progress made in cancer care, cancer is still
a lethal disease and the use of chemotherapy remains
crucial for both curative and palliative purposes. How-
ever, the appropriate use of chemotherapy is still unclear
near death. The subtle difference between curative and
palliative intent when palliative chemotherapy can ex-
tend life is under debate [1]. In addition, patient progno-
sis is complex to predict and the few survival prediction
tools available are not easy to use. To date, there has
been a lack of international guidelines on the manage-
ment of cancer patients near death, except for the
American Society of Clinical Oncology (ASCO) and the
European Society of Medical Oncology [2, 3]. Therefore,
the decision to stop a specific treatment in favor of the
best palliative care is still incredibly hard and the
so-called “therapeutic inertia”, i.e. the persistence of
inappropriate antitumor treatments in non-responding
terminal patients, is frequently used. Such overly aggres-
sive care not only affects a patient’s quality of life (QoL)
[4] but, from a healthcare system point of view, it raises
questions about system sustainability given the
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increasing costs of cancer care (about 20% per year in
the U.S. in the period 1990–2020) [5].
Earle et al. identified aggressive care near the end of
life (EoL) as a sign of poor quality cancer services [6]
and proposed quality indicators of cancer care for exter-
nal benchmarking. Three major areas were evaluated: a)
possible misuse of treatment resulting in high rates of
emergency room visits, hospitalization, or intensive care
unit admission; b) lack of referral or very late referral to
hospice; c) overuse of chemotherapy very near to death
[7]. Although numerous studies have measured some of
these indicators, different criteria were used to define
populations of interest, making a comparison of results
more difficult.
In the present paper we report our data from a retro-
spective cohort study conducted at our institute (IRST
IRCCS) in which we assessed the behavior of physicians
towards chemotherapy prescription and the access of
terminal colorectal cancer (CRC) patients to hospice
care. Our objectives were to gain better knowledge have
a better knowledge of the quality of cancer care services
in our institute, and a deeper insight into how we man-
age end-of-life EoL care in a subset of patients. In
particular, we aimed to report the frequency of some
internationally acknowledged indicators of quality cancer
care and to identify whether some factors related to
patient characteristics or the organization of services
provided can affect the use of chemotherapy and the re-
ferral to hospice care at EoL.
Methods
Study design and participants
We conducted a retrospective analysis of the electronic
medical data of metastatic CRC patients with candidate
to receive chemotherapy. We included all the consecu-
tive patients resident in the catchment area of Forlì
(188,357 inhabitants ref. year 2013) and in the adjacent
area of Cesena Local Health Authority (AUSL) (209,622
inhabitants ref. year 2013) who were candidates to
receive chemotherapy in a metastatic setting from 1
January 2007 to 30 June 2014 and had died before 31
December 2014. The following information was col-
lected for each patient: age of death, gender, number of
lines received for advanced disease, date of last cycle of
chemotherapy and date of start of last new line of ther-
apy. ECOG Performance Status information was
collected on the day of the last chemotherapy line pre-
scription and on the day of the last administration, or in
a time range varying from the day of the last administra-
tion and 7 days before administration.
With regard to access to palliative care, analysis was
possible only for a subgroup of patients who were resi-
dent in the Forlì catchment area and who died between
February 2009 and December 2014, since registration of
access to the palliative care network was recorded from
February 2009 onwards. As cancer patients living in the
two neighboring areas of Forlì and Cesena are followed
by our cancer institute, we were able to verify the homo-
geneity of the two populations by gender, age, previous
treatment for advanced disease, PS ECOG (0 vs. > 1)
(data not shown).
The date of the first access to palliative care was re-
trieved for patients admitted to hospice or home-based
hospice care for at least 1 day. Results obtained for this
subpopulation can be generalized are representative of
the entire population because patient characteristics
were the same and all patients were followed at our
institute. Patients who had only received best supportive
care and patients enrolled in clinical trials were
excluded.
Description of indicators
To evaluate appropriate prescription of chemotherapy,
we considered 2 indicators proposed by Earle et al. [7]
and measured them on the population of patients receiv-
ing chemotherapy, as follows:
a) proportion of patients who started a new
chemotherapy regimen in the last 30 days of life.
The proposed appropriate threshold of < 2% was set
as standard.
b) proportion of patients who received chemotherapy
administration in the last 14 days of life.
The proposed appropriate threshold of < 10% was set
as standard by Earle et al. [7].
We considered all types of palliative care interventions
which represent constitute the “Local Palliative Care
Network (LPCN)”. The network is divided into two types
of interventions: early palliative care, which is further
divided into outpatient and inpatient care for patients
undergoing chemotherapy, and EoL palliative care,
which is further divided into inpatient hospice care and
home-based hospice care mainly for those who are no
longer amenable to chemotherapy. Although some
authors [8] consider home-based hospice care as a
form of early palliative care, we, together with others
[9–11], regard it as a form of EoL palliative care, as
the average length of stay for patients in this setting
is about 60–90 days.
With regard to early palliative care interventions
during the study period, oncologists did not systematic-
ally refer patients to a palliative care specialist but only
requested their intervention for pain and symptom
management. We did not thus were unable to analyze
the impact of early palliative care on the decision of the
oncologist as to whether or not prescribe administer
chemotherapy.
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We used the following 2 indicators proposed by Earle
et al. [7], measured on the population of patients for
whom the date of access to palliative care was available,
to evaluate appropriate access to hospice services:
– proportion of patients receiving hospice services
before death to compare with the proposed
appropriate threshold of > 55%;
– proportion of the above-mentioned patients admit-
ted to hospice 3 days before death to compare with
the proposed appropriate threshold of < 8%.
The proposed appropriate thresholds were set as
standard by Earle et al. [7].
We then compared our data considering both forms of
EoL palliative care.
Statistical methods
Categorical variables were expressed as frequencies and
percentages, while continuous variables were presented
using median and range.
The relationship between demographic and clinical
characteristics and patient status based on the consid-
ered indicators were analyzed using chi-square, Fisher
exact test or Cochran-Armitage test for trend as appro-
priate. In case of continuous variables, Wilcoxon
Mann-Whitney test was used.
Logistic regression was used to investigate the effect
explanatory variables (age, gender and previous line of
advanced therapy) to evaluate the physician’s behavior in
the management of cancer patients in the last days of life
(last chemotherapy scheme prescription ≤30 days vs. >
30 days to death; last chemotherapy cycle administration
≤14 days vs. > 14 days to death). To describe the associ-
ation, adjusted odds ratios (OR) with 95% profile likeli-
hood confidence intervals (95%CI) were evaluated. A
p-value of < 0.05 was considered statistically significant.
Statistical analyses were carried out with SAS Statistical
software (version 9.3, SAS Institute, Cary, NC, USA).
Results
Population characteristics
We observed 365 patients with metastatic CRC deceased
before 31 December 2014 who had started a new
chemotherapy regimen with palliative intent in at our
Institute between 1 January 2007 and 30 June 2014.
Males were 58.9% and median age was 70 years (33–87)
(Table 1). Considering previous treatment features, 245
patients out of 365 (67.1%) had already received at least
1 chemotherapy treatment in metastatic setting.
Use of chemotherapy
Thirty-six (9.8%) patients out of 365 started a new
chemotherapy regimen in the last month of life, while 26
(7.1%) patients received last chemotherapy administra-
tion within 14 days before death. Out of the former 36
patients receiving a new chemotherapy regimen, 12
(33.3%) received a first-line treatment, 12 (33.3%) a
second-line, 8 (22.2%) a third-line, and 4 (11.2%) >
third-line.
Results showed that, among the patients receiving ag-
gressive chemotherapy approach in the last month of
life, patients aged ≤70 years of age were likely to receive
a more aggressive approach (12.8% vs. 6.8%, p = 0.05)
than older patients. Considering the last chemotherapy
administration in the last 14 days of life, age ≤ 70 years
Table 1 Patient characteristics and factors associated to the use of CT in the EoL
Total
No. (%)
New CT scheme
prescription > 30
days to death No. (%)
New CT scheme
prescription ≤30 days
to death No. (%)
p-value Last CT cycle
administration > 14
days to death No. (%)
Last CT cycle
administration ≤14
days to death No. (%)
p-value
Overall 365 (100.0) 329 (90.1) 36 (9.8) – 339 (92.9) 26 (7.1) –
Gender
Male 215 (58.9) 190 (88.4) 25 (11.6) 0.18 200 (93.0) 15 (7.0) 0.90
Female 150 (41.1) 139 (92.7) 11 (7.3) 139 (92.7) 11 (7.3)
Age
Median (range) 70 (33–87) 71 (33–87) 63.5 (37–83) 0.13 70 (33–87) 62.5 (45–80) 0.09
≤ 70 years 188 (51.5) 164 (87.2) 24 (12.8) 0.05 170 (90.4) 18 (9.6) 0.06
> 70 years 177 (48.5) 165 (93.2) 12 (6.8) 169 (95.5) 8 (4.5)
Period of study inclusion
2007–2010 142 (38.9) 129 (90.9) 13 (9.1) 0.72 136 (95.8) 6 (4.2) 0.09
2011–2014 223 (61.1) 200 (89.7) 23 (10.3) 203 (91.0) 20 (8.9)
Previous treatment for advanced disease
None 120 (32.9) 108 (90.0) 12 (10.0) 0.95 105 (87.5) 15 (12.5) < 0.01
At least one 245 (67.1) 221 (90.2) 24 (9.8) 234 (95.5) 11 (4.5)
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(9.6% vs. 4.5%, p = 0.06) and not having received previ-
ous advanced treatments (p < 0.01) were predictive fac-
tors for aggressive behavior. Neither gender nor years of
treatment (2007–2010 vs. 2011–2014) appeared to influ-
ence the chemotherapy approach (Table 1). These results
were maintained in the multivariate analysis (Fig. 1).
With regard to ECOG Performance Status (PS) at the
start of the last line of chemotherapy (or within the pre-
vious 7 days) (data were available for 192 patients out of
365, 52.6%), we observed that 158 (82.3%) patients had
either ECOG PS 0 or 1, while 34 patients (17.7%) had
either ECOG PS 2 or 3 (Table 2). At the time of the last
chemotherapy administration, ECOG PS was available
for 129 patients out of 365 (35.3%) and was either 0 or 1
for 91 patients (70.6%), and either 2 or 3 for 38 patients
(29.4%). As expected, we found that the distribution of
PS of patients who received both a new chemotherapy
line in the last month of life and the last chemotherapy
administration in the last 14 days of life and those who
did not, was different, worsening for the group of
patients who received chemo in the last period of life.
This factor was not included in the multivariate analysis
due to the high amount of missing data. These results
are maintained in a multivariate analysis (Fig. 1).
Access to hospice services
Regarding access to LPCN, we found that out of 166
patients resident in the Forlì catchment Local health Au-
thority area, 28 (16.9%) patients had never had a pallia-
tive care contact with the LPCN in the advanced setting,
while the remaining 138 (83.1%) had had at least one
contact. In particular, 73 (44%) patients had at least one
early palliative care visit, 124 (74.7%) patients accessed
at least one EoL palliative care service (Hospice inpatient
admission and Home-Care Hospice Program), and 59
(35.5%) patients accessed both EoL palliative care
services. Out of the 124 patients who had access to EoL
palliative care, 9 (7.2%) referred to the hospice in the last
3 days of life (Table 3). A higher, albeit not significant,
percentage of patients who had had an early palliative
consultation (80.8% vs. 69.9%, p = 0.11) accessed the
hospice. However, no difference in terms of appropriate
access (> 3 days from death) to Hospice itself was found
among patients.
Discussion
According to Earle’s criteria, our Institution carries out
an acceptable “therapeutic inertia” in terms of chemo-
therapy administration in the last 14 days of life (7.1%
compared to < 10% proposed by Earle). Nevertheless,
improvements should be made concerning the start of a
new chemotherapy regimen in the last month of life
(9.8% compared to < 2% proposed by Earle). When
considering factors predictive of therapeutic inertia, we
found that age ≤ 70 years was associated with a more
aggressive treatment in both starting a new chemother-
apy line in the last 30 days of life and receiving chemo-
therapy in the last 14 days of life, as confirmed in
literature [12–14]. Although this behavior might be
acceptable from a psychological point of view, it is not
indeed supported by any scientific basis, as highlighted
by earlier studies [13]: a more balanced approach is cur-
rently being studied.
In this study, female gender and treating physician
were no predictor factors, unlike in other studies [15].
Since our Institution is organized into pathology-specific
medical teams, an appointed group of physicians regu-
larly meeting to discuss clinical cases is in charge of the
management of CRC patients, thus reducing bias of
treating physician.
As for the role of PS in the decision making process,
we observed that it is likely to be poorer for patients
very near death. In fact, as expected, PS is poorer in
patients receiving chemotherapy in the last period of life
than in patients not receiving any, due to the different
timing respect to death in which it was measured.
In clinical studies with chemotherapy, eligibility
criteria usually couple a good PS (ECOG 0–1, less
frequently 0–2) with a survival prognosis of at least
3 months. Functional activity indexes can correctly
evaluate disability, but need to be combined and inte-
grated with other parameters in order to assess progno-
sis. Recent evidence from Prigerson [4], that combined
PS values, chemotherapy administration and QoL near
Fig. 1 Clinical factors associated to therapeutic inertia
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death, showed that chemotherapy administration did not
improve QoL for patients with poor PS. On the contrary,
it can be detrimental on QoL for patients with good PS.
Prognosis in advanced cancer patients is a highly
debated topic. For this reason, some tools have been
studied in palliative care. Among them, the Palliative
Prognostic Score (PaP Score) [16–18] has been an accur-
ate tool in several independent terminally ill cancer case
series, classifying the studied population into 3 sub-
groups according to life expectancy and demonstrating
that it could help clinicians to better select those
patients who could actually benefit from a palliative
chemotherapy. Pap Score could be assessed at every
cycle of chemotherapy together with ECOG PS.
Some methodological issues on therapeutic inertia near
death are noteworthy. Many publications [12, 19, 20] have
measured these indicators in different types of cancer and
settings in a non-homogeneous way, changing criteria to
define the population of interest, so that it is almost
impossible to compare data from different institutions.
We could compare our population, representing the
entire population in the catchment area of our Cancer
Institute, with a Canadian study [21] and an Australian
study [15]: our percentage for treatment in the last
14 days is lower than in Canada, while it is similar to
Australia. It is worth mentioning that, like in Australia
but unlike in Canada, we restricted our analysis to CRC
patients, excluding hematological malignancies which
are usually more aggressively treated. In Earle’s publica-
tions, indicators were evaluated on a cohort monitored
by one of the SEER (Surveillance, Epidemiology and End
Results) registry whose Medicare population was >
65 years old, thus not allowing for wide comparability of
percentages.
Focusing on “EoL palliative care interventions” within
LPCN, we found that about 74.7% of our patients that
died of cancer had received EoL palliative care. Overall,
as only 16.9% of colorectal cancer patients had no access
to LPCN during their cancer history, palliative care was
guaranteed to the vast majority of the cancer population
in this setting, and referring to EoL palliative care
services, they were accessed in a timely and appropriate
manner. We found also that referral to early palliative
care consultation can aid subsequent referral to EoL
hospice care.
In order to better understand the role of early pallia-
tive care (EPC) on patient outcome and QoL, our Insti-
tute carried out a randomized clinical trial on patients
with advanced pancreas cancer, confirming that system-
atic EPC significantly improved QoL with respect to
on-demand EPC. A positive impact was also observed
for some indicators of EoL treatment aggressiveness,
including the administration of chemotherapy during
the last 30 days of life [22, 23]. These data confirmed the
findings of Temel, Bakitas and ASCO Provisional
Clinical Opinion, all of which highlighted the benefits of
palliative care combined with standard anticancer
therapies [24–26].
The main limitations of the present study include its
retrospective design and the collection of data per-
formed in a wide time range in a non-homogeneous way
leading to a suboptimal completeness of retrieved data
(i.e. ECOG PS). Moreover, as it was impossible to estab-
lish the reasons for chemotherapy discontinuation, we
Table 2 EoL chemotherapy and PS ECOG distribution
Total
No. (%)
New CT scheme
prescription > 30
days to death No. (%)
New CT scheme
prescription ≤30 days
to death No. (%)
p-value Total
No. (%)
Last CT cycle
administration > 14
days to death No. (%)
Last CT cycle
administration ≤14 days
to death No. (%)
p-value
Overall 192 (100.0) 170 (88.5) 22 (11.5) 129 (100.0) 115 (89.1) 14 (10.9)
PS (ECOG)
0 78 (40.6) 75 (96.2) 3 (3.8) < 0.01 34 (26.4) 32 (94.1) 2 (5.9) 0.01
1 80 (41.7) 74 (92.5) 6 (7.5) 57 (44.2) 51 (89.5) 6 (10.5)
2 28 (14.6) 18 (64.3) 10 (35.7) 35 (27.1) 30 (85.7) 5 (14.3)
3 6 (3.1) 3 (50.0) 3 (50.0) 3 (2.3) 2 (66.7) 1 (33.3)
Table 3 Relationship between early PC consultation and access to EoL-PC (n = 166)
Total Access to EoL Palliative Care
None At least one Before ≤3 days to death Within ≤3 days to death
No. (%) No. (%) No. (%) No. (%) No. (%)
Overall 166 (100.0) 42 (25.3) 124 (74.7) 115 (92.8) 9 (7.2)
Access to early PC consultation
None 93 (56.0) 28 (30.1) 65 (69.9)
At least one 73 (44.0) 14 (19.2) 59 (80.8)
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assumed it was due to progression of disease. Another
limitation is that we hypothesized that death had always
been cancer-related without, however, linking data to a
death registry, which may have resulted in an underesti-
mation of deaths. Despite these limitations, we used
real-world clinical data, as the best informative way that
can change clinical practice. An essential tool for this re-
search was the Electronic Health Records (EHR), which
allow to conduct a variety of research projects, from
retrospective studies to monitoring programs like this
one, that involve all treated patients for estimating the
value of healthcare. Despite the lengthy adoption time of
EHRs, we believe that data collection will improve over
time both quantitatively and qualitatively, overcoming
the limitations of using administrative data only. Our
Institute has recently set up an operative taskforce,
involving clinicians, methodologists, cost management
specialists, and the healthcare direction to regularly
verify clinical outcomes, appropriateness and costs, so
that health resources can be employed to the best.
Conclusions
In conclusion, our assessment of the frequency of some
indicators of cancer care quality shows that, according
to the criteria used, our institute provides a good quality
of care to the CRC patients included in this study. For
the Palliative Care Community, our experience can
contribute to the “culture of measuring” that needs to be
enhanced in EoL care, in order to improve the quality of
care. In this vision, multicenter experiences must be
promoted, including also cost evaluations for a more
complete picture of EoL cancer care.
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